NCT03606538View on ClinicalTrials.gov

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 29, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

PharmacokineticsHepatic Impairment

Interventions

DRUG

Midomafetamine HCl

80 mg midomafetamine HCl

Trial Locations (1)

37920

Alliance for Multispecialty Research, LLC., Knoxville

Sponsors

Lead Sponsor

Lykos Therapeutics

All Listed Sponsors

lead

Lykos Therapeutics

INDUSTRY